An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia

Alzheimer Type Dementia Clinical Trial

Official title: Probable Alzheimer Type Dementia Compare INM-176 1200~1600mg/Day With Donepezil 5~10mg/Day of Safety and Efficacy to Randomization, Multicenter, Double-blind, Double-dummy, Parallel Phase III Clinical Study

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of two fixed dose (1200mg/day, 1600mg/day) of INM-176 (a drug of treating dementia) comparing with donepezil for treatment for patients with Alzheimer type dementia.

Clinical Trial Description

Probable Alzheimer type dementia compare INM-176 1200~1600mg/day with Donepezil 5~10mg/day of safety and efficacy to randomization, multicenter, double-blind, double-dummy, parallel Phase III clinical study. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer Type Dementia
• Dementia

• NCT number: NCT01245530
• Study type: Interventional
• Source: Whanin Pharmaceutical Company
• Status: Completed
• Phase: Phase 3
• Start date: June 2008
• Completion date: March 2011